NCT04104607View on ClinicalTrials.gov

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Castration-Resistant Prostatic Cancer
Interventions
DRUG

CC-1, PSMAxCD3

Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation

Trial Locations (2)

69120

NOT_YET_RECRUITING

University hospital Heidelberg, Heidelberg

72076

RECRUITING

University Hospital Tuebingen, Tübingen

All Listed Sponsors
collaborator

German Cancer Research Center

OTHER

lead

University Hospital Tuebingen

OTHER